HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Author home page(s): Frederick J. Schoen Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Schoen, F. J. Articles by Levy, R. J. Search for Related Content PubMed PubMed Citation Articles by Schoen, F. J. Articles by Levy, R. J. Related Collections Valve disease Related Article

Ann Thorac Surg 2005;79:1072-1080
© 2005 The Society of Thoracic Surgeons

---

Review

Calcification of Tissue Heart Valve Substitutes: Progress Toward Understanding and Prevention

^a Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, the Harvard-MIT Division of Health Sciences and Technology, Boston, Massachusetts
^b Abramson Pediatric Research Center, The Children's Hospital of Philadelphia, University of Pennsylvania, Philadelphia, Pennsylvania

^* Address reprint requests to Dr Schoen, Department of Pathology, Brigham and Women's Hospital, 75 Francis St, Boston, MA 02115 (E-mail: fschoen{at}partners.org).

Calcification plays a major role in the failure of bioprosthetic and other tissue heart valve substitutes. Tissue valve calcification is initiated primarily within residual cells that have been devitalized, usually by glutaraldehyde pretreatment. The mechanism involves reaction of calcium-containing extracellular fluid with membrane-associated phosphorus to yield calcium phosphate mineral deposits. Calcification is accelerated by young recipient age, valve factors such as glutaraldehyde fixation, and increased mechanical stress. Recent studies have suggested that pathologic calcification is regulated by inductive and inhibitory factors, similar to the physiologic mineralization of bone. The most promising preventive strategies have included binding of calcification inhibitors to glutaraldehyde fixed tissue, removal or modification of calcifiable components, modification of glutaraldehyde fixation, and use of tissue cross linking agents other than glutaraldehyde. This review summarizes current concepts in the pathophysiology of tissue valve calcification, including emerging concepts of endogenous regulation, progress toward prevention of calcification, and issues related to calcification of the aortic wall of stentless bioprosthetic valves.

Related Article

Carbodiimide Treatment Dramatically Potentiates the Anticalcific Effect of Alpha-Amino Oleic Acid on Glutaraldehyde-Fixed Aortic Wall Tissue

Peter Zilla, Deon Bezuidenhout, and Paul Human
Ann. Thorac. Surg. 2005 79: 905-910. [Abstract] [Full Text] [PDF]

This article has been cited by other articles:

				E. Pettenazzo, M. Valente, and G. Thiene Octanediol treatment of glutaraldehyde fixed bovine pericardium: evidence of anticalcification efficacy in the subcutaneous rat model Eur. J. Cardiothorac. Surg., August 1, 2008; 34(2): 418 - 422. [Abstract] [Full Text] [PDF]

				A. C. Fiore, M. Rodefeld, M. Turrentine, P. Vijay, T. Reynolds, J. Standeven, K. Hill, J. Bost, D. Carpenter, C. Tobin, et al. Pulmonary valve replacement: a comparison of three biological valves. Ann. Thorac. Surg., May 1, 2008; 85(5): 1712 - 1718. [Abstract] [Full Text] [PDF]

				Y. Bosse, P. Mathieu, and P. Pibarot Genomics: The Next Step to Elucidate the Etiology of Calcific Aortic Valve Stenosis J. Am. Coll. Cardiol., April 8, 2008; 51(14): 1327 - 1336. [Abstract] [Full Text] [PDF]

				W. A. Goetz, T. E. Tan, K. H. Lim, S. L. H. Salgues, N. Grousson, F. Xiong, Y. L. Chua, and J. H. Yeo Truly stentless molded autologous pericardial aortic valve prosthesis with single point attached commissures in a sheep model Eur. J. Cardiothorac. Surg., April 1, 2008; 33(4): 548 - 553. [Abstract] [Full Text] [PDF]

				T. Walther, J. Kempfert, M. A. Borger, J. Fassl, V. Falk, J. Blumenstein, M. Dehdashtian, G. Schuler, and F. W. Mohr Human Minimally Invasive Off-Pump Valve-in-a-Valve Implantation Ann. Thorac. Surg., March 1, 2008; 85(3): 1072 - 1073. [Abstract] [Full Text] [PDF]

				R. F. Padera Jr. and F. J. Schoen Pathology of Cardiac Surgery Card. Surg. Adult, January 1, 2008; 3(2008): 111 - 178. [Full Text]

				P. C Santos, L. R Gerola, I. Casagrande, E. Buffolo, and D. T Cheung Stentless Valves Treated by the L-Hydro Process in the Aortic Position in Sheep Asian Cardiovasc Thorac Ann, October 1, 2007; 15(5): 413 - 417. [Abstract] [Full Text] [PDF]

				P. A. Weber, J. Jouan, A. Matsunaga, E. Pettenazzo, T. Joudinaud, G. Thiene, and C. M.G. Duran Evidence of mitigated calcification of the Mosaic versus Hancock Standard valve xenograft in the mitral position of young sheep. J. Thorac. Cardiovasc. Surg., November 1, 2006; 132(5): 1137 - 1143. [Abstract] [Full Text] [PDF]

				S. Cebotari, A. Lichtenberg, I. Tudorache, A. Hilfiker, H. Mertsching, R. Leyh, T. Breymann, K. Kallenbach, L. Maniuc, A. Batrinac, et al. Clinical Application of Tissue Engineered Human Heart Valves Using Autologous Progenitor Cells Circulation, July 4, 2006; 114(1_suppl): I-132 - I-137. [Abstract] [Full Text] [PDF]

				I. Vesely Heart Valve Tissue Engineering Circ. Res., October 14, 2005; 97(8): 743 - 755. [Abstract] [Full Text] [PDF]